(Q46784432)

25 December 2017

title

Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans (English)

1 reference

25 December 2017

0 references

Tashinga E Bapiro

1

1 reference

25 December 2017

Jane Sayi

2

1 reference

25 December 2017

Julia A Hasler

3

1 reference

25 December 2017

Mary Jande

4

1 reference

25 December 2017

Gerald Rimoy

5

1 reference

25 December 2017

Amos Masselle

6

1 reference

25 December 2017

Collen M Masimirembwa

7

1 reference

25 December 2017

publication date

29 October 2005

1 reference

25 December 2017

European Journal of Clinical Pharmacology

published in

1 reference

25 December 2017

volume

61

1 reference

25 December 2017

issue

10

1 reference

25 December 2017

page(s)

755-761

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1007/s00228-005-0037-3

exact match

0 references

cites work

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-005-0037-3

Quantitative assessment of caffeine partial clearances in man.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-005-0037-3

Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1

21 January 2018

1 reference

12 December 2020

Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function

1 reference

12 December 2020

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.

1 reference

12 December 2020

Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults

1 reference

12 December 2020

Theophylline-thiabendazole drug interaction.

1 reference

12 December 2020

Theophylline and antiparasitic drug interactions. A case report and study of the influence of thiabendazole and mebendazole on theophylline pharmacokinetics in adults

1 reference

12 December 2020

Treatment strategies in controlling strongyloidiasis

1 reference

12 December 2020

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

1 reference

12 December 2020

An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates

1 reference

12 December 2020

Clinical pharmacokinetics of anthelmintic drugs

1 reference

12 December 2020

The rational selection of drug interaction studies: implications of recent advances in drug metabolism.

1 reference

12 December 2020

Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration

1 reference

12 December 2020

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus

1 reference

12 December 2020

1 reference

12 December 2020

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

1 reference

12 December 2020

Treatment of widespread cutaneous larva migrans with thiabendazole

1 reference

12 December 2020

Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

1 reference

12 December 2020

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test

1 reference

12 December 2020

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

12 December 2020

Theophylline metabolism in human liver microsomes: inhibition studies.

1 reference

12 December 2020

Predicting the clearance of CYP2C9 substrates.

1 reference

12 December 2020

The pharmacokinetics of thiabendazole and its metabolites in an anephric patient undergoing hemodialysis and hemoperfusion

1 reference

12 December 2020

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine

1 reference

12 December 2020

Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells

1 reference

12 December 2020

Dose-dependency of caffeine metabolism with repeated dosing

1 reference

12 December 2020

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

12 December 2020

Anthelmintics: a review

1 reference

12 December 2020

Current status of artemisinin and its derivatives as antimalarial drugs

1 reference

12 December 2020

Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s

1 reference

12 December 2020

Effect of thiabendazole on some rat hepatic xenobiotic metabolising enzymes

1 reference

12 December 2020

Pharmacokinetics of artemisinin-type compounds

1 reference

12 December 2020

10.1007/S00228-005-0037-3

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017